Literature DB >> 3698092

Methylergometrine, an active metabolite of methysergide.

E Müller-Schweinitzer, C Tapparelli.   

Abstract

In conscious dogs methysergide (MS) caused constriction of the saphenous vein at about 3000 times lower doses than methylergometrine (MT) when infused locally, but it elicited only a short-lasting venoconstrictor response when injected systemically intravenously. MS and MT proved to be equally active venoconstrictor agents when administered orally. Analysis of canine plasma by high-performance liquid chromatography showed that after both oral and intravenous administration of MS large amounts of MT appeared in the plasma, whereas only low and transient levels of MS could be detected. It is suggested that one of the first steps in metabolism of MS is demethylation at position 1 of the indole, leading to the formation of MT, which may be a main active principle of the therapeutic effectiveness of MS in the interval treatment of migraine headache.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698092     DOI: 10.1046/j.1468-2982.1986.0601035.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  Actions of non-peptide ergot alkaloids at 5-HT1-like and 5-HT2 receptors mediating vascular smooth muscle contraction.

Authors:  S J MacLennan; G R Martin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 2.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 3.  5-HT2 receptor antagonists and migraine therapy.

Authors:  E J Mylecharane
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

4.  Pharmacokinetics of methylergometrine in the rat: evidence for enterohepatic recirculation by a linked-rat model.

Authors:  U Bredberg; L Paalzow
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

5.  Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD).

Authors:  Simon D Brandt; Pierce V Kavanagh; Folker Westphal; Alexander Stratford; Simon P Elliott; Khoa Hoang; Jason Wallach; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2015-10-12       Impact factor: 3.345

6.  Methylergometrine antagonizes 5 HT in the temporal artery.

Authors:  P Tfelt-Hansen; I Jansen; L Edvinsson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Efficacy and tolerability of intravenous methylergonovine in migraine female patients attending the emergency department: a pilot open-label study.

Authors:  Alfredo I Niño-Maldonado; Gary Caballero-García; Wilfrido Mercado-Bochero; Fernando Rico-Villademoros; Elena P Calandre
Journal:  Head Face Med       Date:  2009-11-08       Impact factor: 2.151

8.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.